Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Condition(s):Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Large Cell Lymphoma; Refractory Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Hodgkin Lymphoma; Refractory Childhood Malignant Germ Cell Neoplasm; Recurrent Childhood Brain Tumor; Recurrent Childhood Brainstem Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Ependymoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Gliosarcoma; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Neoplasm; Refractory Childhood Malignant NeoplasmLast Updated:August 31, 2023Recruiting